Details of the Drug

General Information of Drug (ID: DMF8FK3)

Drug Name
Tisotumab vedotin
Indication
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Approved [1]
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
ATC Code
L01FX23: Tisotumab vedotin
L01FX: Other monoclonal antibodies and antibody drug conjugates
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Cross-matching ID
UNII
T41737F88A
DrugBank ID
DB16732
TTD ID
D0A4GQ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue factor (F3) TT38MDJ TF_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761208.
2 ClinicalTrials.gov (NCT03245736) Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)